arrow
M

Marta Schirripa

belcolle hospital
H指数:33
被引数:4,133

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting

根据TOPAZ-1研究入组标准评估顺铂、吉西他滨和度伐利尤单抗的疗效:一项真实世界环境下的全球性大规模分析

2026-08-160
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Role and Characteristic of Multidisciplinarity in Hepatocellular Carcinoma Management and Care Pathway Certification: Bottom-Up Approach of the MDT Project in Italy

多学科性在肝细胞癌管理及护理路径认证中的角色与特征:意大利MDT项目的自下而上方法

2026-05-200
OAAI
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab

接受顺铂、吉西他滨和度鲁特韦治疗的胆道癌患者中,转移部位对预后的影响

2026-02-270
PRE
Clinicomics for Predicting HER2 Expression in Metastatic Colorectal Cancer: A Multicenter Machine Learning Analysis on Real-World Data

Clinicomics在预测转移性结直肠癌HER2表达中的应用:一项基于真实世界数据的 multicenter 机器学习分析

2025-12-010
PRE
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study

真实世界证据:regorafenib剂量递增与固定剂量在难治性转移性结直肠癌中的比较:ReTrITA研究的结果

2025-10-140
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study

静脉血栓栓塞风险在癌症患者接受积极系统性治疗后接种第三剂SARS-CoV-2 mRNA-BNT162b2疫苗后不会增加:Vax-On-Third-Profile研究更新结果

2025-04-080
OA
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Durvalumab联合吉西他滨和顺铂治疗晚期胆道癌: 大量现实世界人口

2024-09-013
PRE
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
2024-05-019
PRE
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis
2024-04-131
OAAI
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
2024-02-125
PRE
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study
2024-01-200
OAAI
Predictive and prognostic impact of primary tumor location on sequential treatment with regorafenib and trifluridine/tipiracil at third line and beyond in metastatic colorectal cancer: A real-world multicenter retrospective analysis
2023-10-011
PRE
Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

伦伐替尼治疗肝细胞癌患者食管胃底静脉曲张破裂出血的发生率和预测因素

2023-09-143
OAAI